Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice

Authors:

Abstract
Marked elevation in the brain concentration of N‐acetyl‐L‐aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA‐cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young‐adult aspartoacylase‐deficient mice reverses their pre‐existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480–485
Funding Information
  • National Institutes of Health (R21NS096004, RO1NS094559)
  • Shriners Hospitals for Children (85113‐NCA1B)
  • Dana Foundation (none)

This publication has 21 references indexed in Scilit: